Gliptins-do they increase cardiovascular risk or benefit?

Expert Opinion on Drug Safety

Volumn 13, Issue 5, 2014, Pages 675-680

  Doggrell, Sheila A ^a   Dimmitt, Simon B ^b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Alogliptin; Cardiovascular benefit; Cardiovascular risk; Clinical trials; Saxagliptin; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SAXAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; PIPERIDINE DERIVATIVE; URACIL;

ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; OUTCOMES RESEARCH; ANALOGS AND DERIVATIVES; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; MYOCARDIAL INFARCTION;

ADAMANTANE; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIAL INFARCTION; PIPERIDINES; URACIL;

EID: 84899109176     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.904284     Document Type: Article

References (18)

1. Ligaray KPL, Isley WL. Diabetes mellitus, type 2. Available from: http://emedicine.medscape.com/article/117853- overview [Accessed 24 September 2013]
2. Stratton IM, Adler AI, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
3. Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011;60:298-305
4. FDA announces new recommendations on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes. Available from http://www.fda.gov/ Newsevents/Newsroom/PressAnnouncements/2008/ucm116994. htm [Accessed 27 November 2013]
5. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
6. Nissen SE, Wolski K. Rosiglitazone revisited: and updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201
7. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18
8. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/news- and-events/news/2010/09/news-detail-001119.jsp&murl=menus/news-and-events/ news-and-events. jsp&mid=WC0b01ac058004d5c1 [Accessed 27 November 2013]
9. FDA Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetes therapies to treat type 2 diabetes. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071627.pdf [Accessed 11 December 2013]
10. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
11. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Eng J Med 2013;369:1317-26
12. White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:688-73
13. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
14. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-inhibitors and cardiovascular outcomes: a meta-analysis of randomized clinical trials. Available from: http://www.asceptasm.com/wpcontent/uploads/2013/06/ ASCEPTabstracts- 202-315.pdf [Accessed 26 February 2014]
15. Green JB, Bethel MA, Paul SK, et al. Rational, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983-9.e7
16. Johansen OE, Neubacher D, Von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated metaanalysis or a phase 3 programme. Cardiovasc Diabetol 2012,doi:10.1186/1475-2840-11-3
17. CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. Available from: http://clinicaltrials.gov/ct2/ show/NCT01243424? term=linagliptin&rank=23 [Accessed 28 November 2013].
18. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-20